{"id":4518,"date":"2019-08-20T18:12:19","date_gmt":"2019-08-20T15:12:19","guid":{"rendered":"http:\/\/www.alfapatent-stanadvoka.com\/?p=4518"},"modified":"2021-01-12T21:05:36","modified_gmt":"2021-01-12T18:05:36","slug":"t0012-15","status":"publish","type":"post","link":"https:\/\/www.alfapatent-stanadvoka.com\/tr\/t0012-15\/","title":{"rendered":"20.08.2019 \/T 0012\/15 \/COMPOSITIONS COMPRISING PUFAs, B VITAMINS \/NUTRICIA"},"content":{"rendered":"

EP 1 443 920<\/a>\u00a0patentinin itiraz prosed\u00fcr\u00fcnde iptal karar\u0131 patent sahibi taraf\u0131ndan temyiz edilmi\u015ftir. \u0130ptal edilen ana istem a\u015fa\u011f\u0131da verilmi\u015ftir:<\/p>\n

\u201cA preparation for use in the treatment of a disorder selected from Parkinson’s disease, Huntington’s chorea, epilepsy, schizophrenia, paranoia, depression, sleep disorders, impaired memory function, psychoses, dementia and ADHD, said preparation comprising:<\/p>\n

i) polyunsaturated fatty acids comprising at least docosahexaenoic acid;<\/p>\n

ii) one or more components which have a beneficial effect on total methionine metabolism selected from the group consisting of vitamin B12, vitamin B6, folic acid, zinc and magnesium;<\/p>\n

iii) at least 50 mg nucleobases, including uridine or cytidine, or the phosphates thereof, per daily dose.\u201d<\/p><\/blockquote>\n

\u0130tiraz Birimi\u2019nin patentin iptal karar\u0131 arkas\u0131nda yatan husus muskarinik M1 resept\u00f6r\u00fcn\u00fcn ana istemde tan\u0131ml\u0131 olan bunama d\u0131\u015f\u0131ndaki di\u011fer rahats\u0131zl\u0131klar kar\u015f\u0131s\u0131ndaki teknik etkisine ili\u015fkin kan\u0131t yetersizli\u011fidir. Patent sahibi temyiz dilek\u00e7esiyle birlikte s\u00f6z konusu teknik etkinli\u011fi kan\u0131tlamak i\u00e7in D52 dok\u00fcman\u0131n\u0131 dosyalam\u0131\u015ft\u0131r. S\u00f6z konusu dok\u00fcman kurul taraf\u0131ndan prosed\u00fcre kabul edilmi\u015ftir.
\n\u0130nceleme konusu patent uyar\u0131nca sinyal iletim yollar\u0131nda yer alan resept\u00f6rler bunlara ba\u011flanan bile\u015fenler taraf\u0131ndan aktive edilirler. Spesifik bir resept\u00f6r s\u0131n\u0131f\u0131 ise n\u00f6rotransmitterler taraf\u0131ndan kontrol edilen sinir h\u00fccresi resept\u00f6rleridir. N\u00f6rotransmiterlerin veya n\u00f6romod\u00fclat\u00f6rlerin konsantrasyonunun azalmas\u0131 veya resept\u00f6r\u00fcn n\u00f6rotransmiterlere duyarl\u0131l\u0131\u011f\u0131n\u0131n azalmas\u0131 nedeniyle n\u00f6rotransmitter fonksiyonlar\u0131ndaki bozukluklar, inceleme konusu patentin ana isteminde tan\u0131ml\u0131 bozukluklarda da n\u00f6rolojik rol oynamaktad\u0131r. Patent tarifnamesi ayr\u0131ca terap\u00f6tik etkinin temel olarak PUFA’lar\u0131n (Polyunsaturated fatty acid) istemdeki ii) maddesindeki bile\u015fenler ile bir arada sinerjik etkisine dayand\u0131\u011f\u0131n\u0131 a\u00e7\u0131klamaktad\u0131r. Temyiz Kurulu bu teknik etkilerin konu hakk\u0131nda uzman kimse i\u00e7in makul kabul edilebilir (plausible) oldu\u011funa kanaat getirmi\u015ftir.<\/p>\n

Di\u011fer yandan kar\u015f\u0131 taraf muskarinik M1 resept\u00f6r\u00fc aktivitesi ile \u00f6rne\u011fin epilepsi, Parkinson, Huntington rahats\u0131zl\u0131\u011f\u0131, \u015fizofreni, depresyon ve uyku bozuklu\u011fu gibi istemde yer alan di\u011fer rahats\u0131zl\u0131klar aras\u0131ndaki ili\u015fkinin ispatlanamad\u0131\u011f\u0131n\u0131 iddia etmektedir. Kurul T 1311\/15 ve T 2001\/12 teknik Temyiz Kurulu kararlar\u0131 uyar\u0131nca\u00a0istemde talep konusu yap\u0131lmayan bir teknik etkiye dayanan bir a\u00e7\u0131klama yetersizli\u011fi itiraz\u0131n\u0131n dikkate al\u0131nmayaca\u011f\u0131n\u0131<\/u>\u00a0hat\u0131rlatm\u0131\u015ft\u0131r.<\/p>\n

Temyiz Kurulu yapt\u0131\u011f\u0131 incelemede patent sahibinin muskarinik M1 resept\u00f6r\u00fc aktivitesini ispatlamak \u00fczere sundu\u011fu kan\u0131tlardan ve yapt\u0131\u011f\u0131 a\u00e7\u0131klamalardan hareketle teknik etkinin \u201cplausible\u201d oldu\u011fu konusunda ikna olmam\u0131\u015ft\u0131r. \u0130ptal karar\u0131 onanm\u0131\u015ft\u0131r.<\/p>\n","protected":false},"excerpt":{"rendered":"

EP 1 443 920\u00a0patentinin itiraz prosed\u00fcr\u00fcnde iptal karar\u0131 patent sahibi taraf\u0131ndan temyiz edilmi\u015ftir. \u0130ptal edilen ana istem a\u015fa\u011f\u0131da verilmi\u015ftir: \u201cA<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[112],"tags":[],"class_list":["post-4518","post","type-post","status-publish","format-standard","hentry","category-t-kararlar"],"_links":{"self":[{"href":"https:\/\/www.alfapatent-stanadvoka.com\/tr\/wp-json\/wp\/v2\/posts\/4518","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.alfapatent-stanadvoka.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.alfapatent-stanadvoka.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.alfapatent-stanadvoka.com\/tr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.alfapatent-stanadvoka.com\/tr\/wp-json\/wp\/v2\/comments?post=4518"}],"version-history":[{"count":3,"href":"https:\/\/www.alfapatent-stanadvoka.com\/tr\/wp-json\/wp\/v2\/posts\/4518\/revisions"}],"predecessor-version":[{"id":5076,"href":"https:\/\/www.alfapatent-stanadvoka.com\/tr\/wp-json\/wp\/v2\/posts\/4518\/revisions\/5076"}],"wp:attachment":[{"href":"https:\/\/www.alfapatent-stanadvoka.com\/tr\/wp-json\/wp\/v2\/media?parent=4518"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.alfapatent-stanadvoka.com\/tr\/wp-json\/wp\/v2\/categories?post=4518"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.alfapatent-stanadvoka.com\/tr\/wp-json\/wp\/v2\/tags?post=4518"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}